MX390092B - Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico - Google Patents
Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólicoInfo
- Publication number
- MX390092B MX390092B MX2017014111A MX2017014111A MX390092B MX 390092 B MX390092 B MX 390092B MX 2017014111 A MX2017014111 A MX 2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A MX 390092 B MX390092 B MX 390092B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- metabolic status
- barrier function
- intestinal barrier
- immune signaling
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 235000020938 metabolic status Nutrition 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title 1
- 230000007358 intestinal barrier function Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 210000000987 immune system Anatomy 0.000 abstract 2
- 230000004682 mucosal barrier function Effects 0.000 abstract 2
- 241000702460 Akkermansia Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166598 | 2015-05-06 | ||
| PCT/EP2016/060033 WO2016177797A1 (en) | 2015-05-06 | 2016-05-04 | Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014111A MX2017014111A (es) | 2018-02-26 |
| MX390092B true MX390092B (es) | 2025-03-11 |
Family
ID=74184294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014111A MX390092B (es) | 2015-05-06 | 2016-05-04 | Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10738089B2 (enExample) |
| EP (1) | EP3292135B1 (enExample) |
| JP (1) | JP6894382B2 (enExample) |
| KR (1) | KR102736980B1 (enExample) |
| CN (1) | CN107980043B (enExample) |
| AU (2) | AU2016257315A1 (enExample) |
| DK (1) | DK3292135T3 (enExample) |
| EA (1) | EA201700507A1 (enExample) |
| ES (1) | ES2934138T3 (enExample) |
| HK (1) | HK1252412A1 (enExample) |
| IL (1) | IL255405B (enExample) |
| MX (1) | MX390092B (enExample) |
| PL (1) | PL3292135T3 (enExample) |
| WO (1) | WO2016177797A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703395PA (en) | 2014-10-31 | 2017-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3292135B1 (en) | 2015-05-06 | 2022-09-21 | Wageningen Universiteit | Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
| PL3626081T3 (pl) * | 2015-09-10 | 2022-04-25 | Université Catholique de Louvain | Pasteryzowane bakterie akkermansia w leczeniu zaburzeń metabolicznych |
| WO2018165338A2 (en) * | 2017-03-07 | 2018-09-13 | uBiome, Inc. | Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof |
| US20200246488A1 (en) * | 2017-07-17 | 2020-08-06 | The Broad Institute, Inc. | Compositions and methods for treating inflammatory bowel diseases |
| JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス， インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
| EP3823651A4 (en) | 2018-07-19 | 2022-04-27 | Pendulum Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION |
| KR102340392B1 (ko) * | 2018-10-08 | 2021-12-17 | 한국생명공학연구원 | 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도 |
| KR102197180B1 (ko) | 2018-10-11 | 2020-12-31 | 주식회사 고바이오랩 | 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물 |
| CN110079474B (zh) * | 2019-04-12 | 2022-11-25 | 沈阳药科大学 | 一种高密度培养艾克曼嗜黏蛋白菌的方法 |
| KR102263030B1 (ko) * | 2019-05-07 | 2021-06-10 | 한국생명공학연구원 | 염증성 장질환의 예방 또는 치료용 펩타이드 |
| CN110227085A (zh) * | 2019-07-16 | 2019-09-13 | 江苏省中医院 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
| EP4079837A4 (en) * | 2019-09-25 | 2024-06-05 | HealthBiome, Inc. | OBLIGATE ANAEROBIC HUMAN INTESTINAL MICROBES FOR CANCER TREATMENT AND ITS USE |
| KR102397916B1 (ko) * | 2019-10-01 | 2022-05-17 | (주)헬스바이옴 | 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법 |
| CN110950937B (zh) * | 2019-11-25 | 2021-05-04 | 安徽大学 | 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用 |
| CN115315433A (zh) * | 2020-01-10 | 2022-11-08 | 黄志宏 | Tlr2交互作用的胜肽以及包括其的组合物 |
| KR102671044B1 (ko) * | 2020-03-25 | 2024-05-31 | 한국생명공학연구원 | 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도 |
| US20210322492A1 (en) * | 2020-04-16 | 2021-10-21 | Amucin Oy Ltd | Probiotic strains and uses thereof |
| CN111690044B (zh) * | 2020-05-06 | 2022-03-01 | 中南大学湘雅二医院 | Amuc1100蛋白的用途 |
| AU2021299904A1 (en) | 2020-07-01 | 2023-01-19 | Advanced Microbiome Interventions B.V. | Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
| WO2022098051A1 (ko) * | 2020-11-05 | 2022-05-12 | 한국생명공학연구원 | 항염 및 조직 재생작용을 갖는 신규 펩타이드 |
| CN113413466B (zh) * | 2020-12-15 | 2022-08-19 | 和度生物医药(上海)有限公司 | 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法 |
| CN115364198A (zh) * | 2022-08-23 | 2022-11-22 | 广州康泽医疗科技有限公司 | 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用 |
| CN116059254B (zh) * | 2023-02-27 | 2025-04-18 | 广州知易生物科技有限公司 | 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用 |
| KR102835266B1 (ko) | 2023-09-11 | 2025-07-17 | 충남대학교산학협력단 | 아커만시아 뮤시니필라 m3-2 균주 및 이의 용도 |
| CN117304264B (zh) * | 2023-11-27 | 2024-02-06 | 中国科学院烟台海岸带研究所 | 一种具有肠屏障保护功能的五肽rp5及其应用 |
| CN118063567B (zh) * | 2024-03-03 | 2025-11-21 | 吉林大学 | 一种用于炎性肠病治疗的重组蛋白的制备与应用 |
| CN119874827B (zh) * | 2025-03-27 | 2025-06-13 | 杭州康源食品科技有限公司 | 一种具有免疫调节作用的九肽及其制备和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
| NL1014380C2 (nl) | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Darmwandversterkend voedingsmiddel. |
| US7253333B2 (en) * | 2001-02-28 | 2007-08-07 | National Institute Of Advanced Industrial Science And Technology | Drosophila strain carrying bradeion gene(s) transferred thereinto |
| EP1583548A4 (en) * | 2002-12-10 | 2007-10-17 | Epimmune Inc | HLA-A1, A2 -A3, -A24, -B7 AND B44TUMOR ASSOCIATED ANTIGENPEPTIDES AND COMPOSITIONS |
| US20050180962A1 (en) | 2003-01-30 | 2005-08-18 | Eyal Raz | Inactivated probiotic bacteria and methods of use thereof |
| WO2005030133A2 (en) * | 2003-09-22 | 2005-04-07 | Yale University | Treatment with agonists of toll-like receptors |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| US7812121B2 (en) | 2006-08-31 | 2010-10-12 | Baker Audrey E | GLP-2 mimetibodies, polypeptides, compositions, methods and uses |
| WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
| EP2030623A1 (en) | 2007-08-17 | 2009-03-04 | Nestec S.A. | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| FR2944524B1 (fr) | 2009-04-17 | 2012-11-30 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| CA2761444C (en) | 2009-05-11 | 2018-04-24 | Nestec S.A. | Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders |
| WO2011137369A1 (en) * | 2010-04-29 | 2011-11-03 | The Regents Of The University Of California | Production of gamma-aminobutyric acid by recombinant microorganisms |
| US9104670B2 (en) | 2010-07-21 | 2015-08-11 | Apple Inc. | Customized search or acquisition of digital media assets |
| WO2012052868A2 (en) | 2010-10-20 | 2012-04-26 | Koninklijke Philips Electronics N.V. | Disaggregation apparatus |
| EP2449891A1 (en) | 2010-11-05 | 2012-05-09 | Nestec S.A. | Drinking yoghurt preparations containing non-replicating probiotic micro-organisms |
| ES2565407T3 (es) | 2010-11-05 | 2016-04-04 | Nestec S.A. | Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos |
| IN2014DN07752A (enExample) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| WO2014075745A1 (en) | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| KR101740893B1 (ko) * | 2014-05-20 | 2017-06-13 | 주식회사 엠디헬스케어 | Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 |
| EP3292135B1 (en) | 2015-05-06 | 2022-09-21 | Wageningen Universiteit | Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
| PL3626081T3 (pl) | 2015-09-10 | 2022-04-25 | Université Catholique de Louvain | Pasteryzowane bakterie akkermansia w leczeniu zaburzeń metabolicznych |
| US11071626B2 (en) | 2018-03-16 | 2021-07-27 | W. L. Gore & Associates, Inc. | Diametric expansion features for prosthetic valves |
-
2016
- 2016-05-04 EP EP16724321.1A patent/EP3292135B1/en active Active
- 2016-05-04 CN CN201680026195.4A patent/CN107980043B/zh active Active
- 2016-05-04 KR KR1020177035003A patent/KR102736980B1/ko active Active
- 2016-05-04 PL PL16724321.1T patent/PL3292135T3/pl unknown
- 2016-05-04 EA EA201700507A patent/EA201700507A1/ru unknown
- 2016-05-04 MX MX2017014111A patent/MX390092B/es unknown
- 2016-05-04 ES ES16724321T patent/ES2934138T3/es active Active
- 2016-05-04 US US15/571,175 patent/US10738089B2/en active Active
- 2016-05-04 DK DK16724321.1T patent/DK3292135T3/da active
- 2016-05-04 WO PCT/EP2016/060033 patent/WO2016177797A1/en not_active Ceased
- 2016-05-04 HK HK18111709.9A patent/HK1252412A1/zh unknown
- 2016-05-04 AU AU2016257315A patent/AU2016257315A1/en not_active Abandoned
- 2016-05-04 JP JP2017557983A patent/JP6894382B2/ja active Active
-
2017
- 2017-11-02 IL IL255405A patent/IL255405B/en unknown
-
2020
- 2020-06-30 US US16/916,459 patent/US11466057B2/en active Active
- 2020-11-11 AU AU2020267210A patent/AU2020267210B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107980043A (zh) | 2018-05-01 |
| KR20180011130A (ko) | 2018-01-31 |
| EA201700507A1 (ru) | 2018-05-31 |
| AU2020267210A1 (en) | 2020-12-17 |
| ES2934138T3 (es) | 2023-02-17 |
| IL255405A0 (en) | 2017-12-31 |
| HK1252412A1 (zh) | 2019-05-24 |
| NZ737765A (en) | 2024-08-30 |
| AU2016257315A1 (en) | 2017-11-23 |
| US20180265554A1 (en) | 2018-09-20 |
| WO2016177797A1 (en) | 2016-11-10 |
| US10738089B2 (en) | 2020-08-11 |
| DK3292135T3 (da) | 2022-10-31 |
| MX2017014111A (es) | 2018-02-26 |
| AU2020267210B2 (en) | 2023-10-12 |
| PL3292135T3 (pl) | 2023-01-02 |
| KR102736980B1 (ko) | 2024-12-02 |
| JP2018515502A (ja) | 2018-06-14 |
| EP3292135B1 (en) | 2022-09-21 |
| JP6894382B2 (ja) | 2021-06-30 |
| EP3292135A1 (en) | 2018-03-14 |
| BR112017023751A2 (pt) | 2018-07-31 |
| CN107980043B (zh) | 2021-09-24 |
| CA2984985A1 (en) | 2016-11-10 |
| IL255405B (en) | 2022-01-01 |
| US11466057B2 (en) | 2022-10-11 |
| US20210147489A1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390092B (es) | Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico | |
| EP3837488C0 (en) | IMMEDIATE PROXIMITY COUNTERMEASURES TO NEUTRALIZE TARGET AERIAL VEHICLES | |
| MX2015016356A (es) | Localizacion de dispositivo utilizando camara y señal inalambrica. | |
| EA201791426A1 (ru) | Полипептид и иммуномодуляция | |
| BR112017006664A2 (pt) | terapias de combinação | |
| MX380813B (es) | Células asesinas naturales y líneas de células asesinas naturales modificadas con aumento de la citotoxicidad. | |
| BR112017007543A2 (pt) | peptídeos com propriedades anti-inflamatórias | |
| CL2016000725A1 (es) | Metodo para tratamiento de agua de un lago flotante artificial que comprende: aplicar un oxidante al gua; aplica un floculante; activar la operacion de uno o mas dispositivos de succion movil, filtrar el agua succionada y devolver el agua filtrada a dicho lago; y suministrar agua a dicho lago flotante; y sistema. | |
| CL2015002522A1 (es) | Composiciones y métodos para activar "estimulador de interferon gene" - señalización dependientes. | |
| MX2017005457A (es) | Metodos y compuestos agonistas de gip. | |
| UA118558C2 (uk) | Пептидна сполука | |
| JO3564B1 (ar) | ببتيدات وتركيبات لعلاج ضرر المفاصل | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| CR20170197A (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros | |
| EA201792399A1 (ru) | Пептидные композиции и способы использования | |
| MY184390A (en) | Use of visual cues to enhance bird repellent compositions | |
| BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| MX2021002668A (es) | Plataforma de virus oncolitico para tratar el cancer hematologico. | |
| MX2016007356A (es) | Composicion para administracion oral de agentes bioactivos. | |
| EP3532077A4 (en) | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death | |
| MX2016012085A (es) | Metodos para producir glucoproteinas recombinantes con glucosilacion modificada. | |
| MX2020014151A (es) | Celula hospedadora recombinante que expresa actividad de beta-galactosidasa y/o transgalactosidante deficiente en mananasa, celulasa y pectinasa. | |
| BR112018075613A2 (pt) | peptídeos para o tratamento de osteoartrite | |
| IL287040A (en) | Systems and methods for isolating microvessels from adipose tissue |